144 related articles for article (PubMed ID: 10592453)
1. Norditropin SimpleXx: a liquid human growth hormone formulation, a pen system and an auto-insertion device.
Müller J; Skakkebaek NE; Jacobsen BB; Keller E; Heinrich U; Hartmann K; Hokken-Koelega AC; Delemarre van de Waal HA
Horm Res; 1999; 51 Suppl 3():109-12. PubMed ID: 10592453
[TBL] [Abstract][Full Text] [Related]
2. The clinical usefulness of liquid human growth hormone (hGH) (Norditropin SimpleXx in the treatment of GH deficiency.
Iyoda K; Moriwake T; Seino Y; Niimi H
Horm Res; 1999; 51 Suppl 3():113-5. PubMed ID: 10592454
[TBL] [Abstract][Full Text] [Related]
3. An open-label acceptability study of Norditropin SimpleXx--a new liquid growth hormone formulation.
Stanhope R; Buchanan C; Butler G; Costigan C; Dunger D; Greene S; Hoey H; Hughes I; Kelnar C; Kirk J; Komulainen J; Lowry M; Warner J
J Pediatr Endocrinol Metab; 2001 Jun; 14(6):735-40. PubMed ID: 11453523
[TBL] [Abstract][Full Text] [Related]
4. Acceptability of Liquid Human Growth Hormone (hGH) [Norditropin Simple Xx®] in Adults and Children with GH Deficiency and Children with Chronic Renal Disease.
Drent ML; Jakobsdottir S; van Wijk JAE; Oostdijk W; Wit JM
Clin Drug Investig; 2002 Sep; 22(9):633-638. PubMed ID: 29492857
[TBL] [Abstract][Full Text] [Related]
5. Ease of use and acceptability of a new pen device for the administration of growth hormone therapy in pediatric patients: an open-label, uncontrolled usability test.
Fuchs GS; Mikkelsen S; Knudsen TK; Kappelgaard AM
Clin Ther; 2009 Dec; 31(12):2906-14. PubMed ID: 20110030
[TBL] [Abstract][Full Text] [Related]
6. Patient preference for a new growth hormone injection device: results of an open-label study in Japanese pediatric patients.
Kappelgaard AM; Mikkelsen S; Knudsen TK; Fuchs GS
J Pediatr Endocrinol Metab; 2011; 24(7-8):489-96. PubMed ID: 21932587
[TBL] [Abstract][Full Text] [Related]
7. Liquid growth hormone: preservatives and buffers.
Kappelgaard AM; Bojesen A; Skydsgaard K; Sjögren I; Laursen T
Horm Res; 2004; 62 Suppl 3():98-103. PubMed ID: 15539807
[TBL] [Abstract][Full Text] [Related]
8. Children and adolescent acceptability of a new device system to administer human growth hormone--a pilot study.
Kappelgaard AM; Mikkelsen S; Bagger C; Fuchs GS
J Pediatr Endocrinol Metab; 2012; 25(3-4):285-94. PubMed ID: 22768658
[TBL] [Abstract][Full Text] [Related]
9. Growth hormone therapy with a new delivery system.
Jørgensen JT; Susgaard S
Indian J Pediatr; 1991; 58 Suppl 1():43-50. PubMed ID: 1824374
[TBL] [Abstract][Full Text] [Related]
10. Product wastage from modern human growth hormone administration devices: a laboratory and computer simulation analysis.
Pollock RF; Qian Y; Wisniewski T; Seitz L; Kappelgaard AM
Med Devices (Auckl); 2013; 6():107-14. PubMed ID: 23946672
[TBL] [Abstract][Full Text] [Related]
11. Ease of use and preference for a new disposable self-injection pen compared with a reusable pen for administering recombinant human growth hormone: A multicenter, 2-month, single-arm, open-label clinical trial in patient-caregiver dyads.
Hey-Hadavi J; Pleil A; Deeb LC; Fuqua JS; Silverman LA; Reiner B; Newfield R; Rajicic N; Wajnrajch MP; Cara JF
Clin Ther; 2010 Nov; 32(12):2036-47. PubMed ID: 21118739
[TBL] [Abstract][Full Text] [Related]
12. User assessment of Norditropin NordiFlex(®), a new prefilled growth hormone pen: a Phase IV multicenter prospective study.
Tauber M; Jaquet D; Jesuran-Perelroizen M; Petrus M; Bertrand AM; Coutant R;
Patient Prefer Adherence; 2013; 7():455-62. PubMed ID: 23737664
[TBL] [Abstract][Full Text] [Related]
13. Growth hormone therapy with norditropin ( somatropin ) in growth hormone deficiency.
Pawlikowska-Haddal A
Expert Opin Biol Ther; 2013 Jun; 13(6):927-32. PubMed ID: 23662811
[TBL] [Abstract][Full Text] [Related]
14. Optimum method for administration of biosynthetic human growth hormone: a randomised crossover trial of an Auto Injector and a pen injection system.
Stanhope R; Albanese A; Moyle L; Hamill G
Arch Dis Child; 1992 Aug; 67(8):994-7. PubMed ID: 1520018
[TBL] [Abstract][Full Text] [Related]
15. Assessment of user-friendliness of the Norditropin FlexPro for pediatric patients treated with recombinant human growth hormone: results of an open-label user survey.
Adachi M
J Pediatr Endocrinol Metab; 2013; 26(11-12):1105-10. PubMed ID: 23843576
[TBL] [Abstract][Full Text] [Related]
16. Psychological responses to the needle-free Medi-Jector or the multidose Disetronic injection pen in human growth hormone therapy.
Verrips GH; Hirasing RA; Fekkes M; Vogels T; Verloove-Vanhorick SP; Delemarre-Van de Waal HA
Acta Paediatr; 1998 Feb; 87(2):154-8. PubMed ID: 9512200
[TBL] [Abstract][Full Text] [Related]
17. Improvement of treatment adherence with growth hormone by easypod™ device: experience of an Italian centre.
Maggio MC; Vergara B; Porcelli P; Corsello G
Ital J Pediatr; 2018 Sep; 44(1):113. PubMed ID: 30261918
[TBL] [Abstract][Full Text] [Related]
18. Development and Psychometric Evaluation of the Life Interference Questionnaire for Growth Hormone Deficiency (LIQ-GHD) to Assess Growth Hormone Injection Burden in Children and Adults.
Turner-Bowker DM; Yaworsky A; Palladino A; Lamoureux RE; Kelly M; Love E; Pleil AM; Shields A; Loftus J
Patient; 2020 Jun; 13(3):289-306. PubMed ID: 31956960
[TBL] [Abstract][Full Text] [Related]
19. Comparison of intuitiveness, ease of use and preference among three prefilled, disposable growth hormone injection pens.
Rohrer TR; Winter F; Qvist M; Kappelgaard AM
Expert Opin Drug Deliv; 2013 Dec; 10(12):1603-12. PubMed ID: 24073645
[TBL] [Abstract][Full Text] [Related]
20. Improvement of patient convenience in treatment with growth hormone.
Jørgensen JT
J Pediatr Endocrinol; 1994; 7(2):175-80. PubMed ID: 8061763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
